Shosha I. Dekker

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Predicting Kidney Outcomes in Autosomal Dominant Polycystic Kidney Disease: A Comprehensive Biomarker Analysis.

Predicting Kidney Outcomes in Autosomal Dominant Polycystic Kidney Disease: A Comprehensive Biomarker Analysis.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: October 20, 2024

Serum bile acids associate with liver volume in polycystic liver disease and decrease upon treatment with lanreotide.

Serum bile acids associate with liver volume in polycystic liver disease and decrease upon treatment with lanreotide.

Journal: European journal of clinical investigation

Published: August 04, 2023

The impact of pre-transplantation nephrectomy on quality of life in patients with autosomal dominant polycystic kidney disease.

The impact of pre-transplantation nephrectomy on quality of life in patients with autosomal dominant polycystic kidney disease.

Journal: World journal of urology

Published: October 07, 2022

Change in Urinary Myoinositol/Citrate Ratio Associates with Progressive Loss of Renal Function in ADPKD Patients.

Change in Urinary Myoinositol/Citrate Ratio Associates with Progressive Loss of Renal Function in ADPKD Patients.

Journal: American journal of nephrology

Published: March 16, 2022

Efficacy and safety of selective decontamination of the digestive tract (SDD) to prevent recurrent hepatic cyst infections in polycystic liver disease: a retrospective case series.

Efficacy and safety of selective decontamination of the digestive tract (SDD) to prevent recurrent hepatic cyst infections in polycystic liver disease: a retrospective case series.

Journal: The Journal of antimicrobial chemotherapy

Published: January 14, 2020

Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease.

Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease.

Journal: PloS one

Published: October 09, 2019

Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor-Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients.

Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor-Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients.

Journal: Kidney international reports

Published: November 28, 2018

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.

Journal: JAMA

Published: November 14, 2018

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.

Journal: Gastroenterology

Published: October 29, 2018

Effects of Water Loading on Observed and Predicted Plasma Sodium, and Fluid and Urine Cation Excretion in Healthy Individuals.

Effects of Water Loading on Observed and Predicted Plasma Sodium, and Fluid and Urine Cation Excretion in Healthy Individuals.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation

Published: September 20, 2018

Showing 1-10 of 10

Last Updated: 09/26/2026